Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na(+)?

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the wistfully awaited results of two clinical trials (DELIVER and EMPEROR-Preserved)—may be the first drug class to improve cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales: Trum, Maximilian, Riechel, Johannes, Wagner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347698/
https://www.ncbi.nlm.nih.gov/pubmed/34360742
http://dx.doi.org/10.3390/ijms22157976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347698/
https://www.ncbi.nlm.nih.gov/pubmed/34360742
http://dx.doi.org/10.3390/ijms22157976

Ejemplares similares